Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Nursing diagnosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    370 result(s) found for: Nursing diagnosis. Displaying page 6 of 19.
    EudraCT Number: 2004-000817-20 Sponsor Protocol Number: 6002-EU-007 Start Date*: 2004-10-22
    Sponsor Name:Kyowa Hakko U.K. Limited
    Full Title: A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (istradefylline) and that of Entac...
    Medical condition: Parkinson's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) AT (Completed) LT (Completed) GB (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-004982-25 Sponsor Protocol Number: BET115521 Start Date*: 2015-08-18
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with NUT midline carcinoma (NMC) and othe...
    Medical condition: NUT Midline Carcinoma and other solid tumors
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10007284 Carcinoma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-010571-24 Sponsor Protocol Number: VEG111109 Start Date*: 2009-08-03
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: An open label, multicenter, Phase I/II study of pazopanib in combination with paclitaxel in first line treatment of subjects with stage IIIBwet/IV non-small cell lung cancer
    Medical condition: Part I: Subjects with histologically or cytologically confirmed diagnosis of advanced solid tumours for which there is no standard therapy or for whom paclitaxel is standard therapy. Part II: Sta...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002154-23 Sponsor Protocol Number: UKM_04_12_TCP_ATRA_AML Start Date*: 2014-08-28
    Sponsor Name:Martin-Luther-University Halle-Wittenberg
    Full Title: Phase I/II pilot trial of ATRA (Tretinoin) and TCP (Tranylcypromine) in patients with relapsed or refractory acute myeloid leukemia (AML) when no intensive treatment is possible
    Medical condition: relapse or refractory AML in patients unfit for an intensive treatment
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002245-12 Sponsor Protocol Number: EORTC 18021 Start Date*: 2005-01-27
    Sponsor Name:European Organisation for the Research and Treatment of Cancer
    Full Title: Intravenous versus intra-arterial fotemustine chemotherapy in patients with liver metastases from uveal melanoma: a randomized phase III study of the EORTC Melanoma Group.
    Medical condition: Uveal melanomas with specific hepatic tropism
    Disease: Version SOC Term Classification Code Term Level
    13.1 10015919 - Eye disorders 10030052 Ocular melanomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002780-27 Sponsor Protocol Number: GAL-ALZ-3005 Start Date*: 2008-08-26
    Sponsor Name:Janssen Cilag International NV
    Full Title: A Randomized, Double-blind, Placebo-controlled Trial of Long-term (2-year) Treatment of Galantamine in Mild to Moderately-severe Alzheimer’s Disease
    Medical condition: Mild to moderately severe Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) LT (Completed) LV (Prematurely Ended) EE (Prematurely Ended) CZ (Prematurely Ended) SI (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended) AT (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2013-001913-34 Sponsor Protocol Number: TP-434-008 Start Date*: 2013-08-16
    Sponsor Name:Tetraphase Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared with Ertapenem in Complicated Intra-abdominal Infections
    Medical condition: Complicated Intra-abdominal Infections
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10056570 Intra-abdominal infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) CZ (Completed) EE (Completed) LT (Completed) DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-002208-21 Sponsor Protocol Number: TP-434-025 Start Date*: 2016-09-27
    Sponsor Name:Tetraphase Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared with Meropenem in Complicated Intra-abdominal Infections
    Medical condition: Complicated Intra-abdominal Infections
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10056570 Intra-abdominal infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) LV (Completed) EE (Completed) LT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2004-000654-23 Sponsor Protocol Number: EORTC 18032 Start Date*: 2004-12-09
    Sponsor Name:EORTC
    Full Title: Extended schedule, escalated dose Temozolomide versus Dacarbazine in Stage IV Metastatic Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group
    Medical condition: Stage IV Metastatic Melanoma:
    Disease: Version SOC Term Classification Code Term Level
    7.0 10027480 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-013680-19 Sponsor Protocol Number: 541/09 Start Date*: 2009-12-18
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Phase II, Open, Monocenter Study to investigate the efficacy of Propionyl-L-carnitine (ST 261) Colon Release Tablets in Patients Affected by Inflammatory Bowel Disease (IBD) under Oral Stable Trea...
    Medical condition: IBD
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011401 PT
    9.1 10045282 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003659-63 Sponsor Protocol Number: BGC20-1259-04 Start Date*: 2009-03-13
    Sponsor Name:BTG International Ltd
    Full Title: A multicentre double-blind, placebo-controlled, randomised, parallel-group study to evaluate the safety and efficacy of BGC20-1259 in patients with mild to moderate probable Alzheimer’s Disease.
    Medical condition: Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004413-33 Sponsor Protocol Number: KBT-004 Start Date*: 2007-10-26
    Sponsor Name:Karo Bio AB
    Full Title: A Phase II, Placebo-Controlled, Double-Blind, Randomised, 12-Week, Parallel-group Study to Assess the Efficacy of Different Doses of KB 2115 as add on to Statin Treatment in Patients With Dyslipid...
    Medical condition: Primary hypercholesterolaemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020603 Hypercholesterolaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2015-000463-13 Sponsor Protocol Number: MGR001-1010 Start Date*: 2015-05-05
    Sponsor Name:Mylan Pharma UK Ltd
    Full Title: AN OPEN STUDY TO ASSESS THE ROBUSTNESS OF THE CRC749 DEVICE BY PHARMACEUTICAL PERFORMANCE FOLLOWING TWICE DAILY DOSING OF MGR001 ADMINISTERED VIA ORAL INHALATION IN SUBJECTS WITH ASTHMA OR CHRONIC ...
    Medical condition: Asthma or chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000241-21 Sponsor Protocol Number: BEL114870 Start Date*: 2011-06-23
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A clinical and mechanistic proof of efficacy study with belimumab in chronic immune thrombocytopenia (ITP) patients
    Medical condition: Chronic Immune Thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10051057 Idiopathic thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002848-93 Sponsor Protocol Number: UMCN-AKF13.02 Start Date*: 2014-01-23
    Sponsor Name:Radboud University Medical Centre
    Full Title: Pharmacokinetics of micafungin (Mycamin ®) as antifungal prophylaxis given twice weekly intravenously compared to micafungin given daily to patients at risk for developing an invasive fungal disease.
    Medical condition: prophylaxis for patients at high risk for invasive fungal diseases
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10017533 Fungal infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003547-38 Sponsor Protocol Number: ALLN-177-206 Start Date*: 2018-07-17
    Sponsor Name:Allena Pharmaceuticals, Inc.
    Full Title: Pilot Study of ALLN-177 in Adult and Pediatric Subjects Aged 12 Years or Older with Enteric or Primary Hyperoxaluria and Hyperoxalemia
    Medical condition: Enteric or primary hyperoxaluria and hyperoxalemia
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001182-87 Sponsor Protocol Number: UMCN-AKF16.01 Start Date*: 2017-01-10
    Sponsor Name:Radboud University Medical Centre
    Full Title: Pharmacokinetics of posaconazole (Noxafil(R)) as prophylaxis for invasive fungal disease
    Medical condition: prophylaxis for patients at high risk for invasive fungal diseases
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10017533 Fungal infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011889-28 Sponsor Protocol Number: AMLSG09-09 Start Date*: 2010-02-08
    Sponsor Name:University of Ulm
    Full Title: Phase III study of chemotherapy in combination with ATRA with or without gemtuzumab ozogamicin in patients with acute myeloid leukemia and NPM1 gene mutation
    Medical condition: adult patients with AML and NPM1 mutation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001187-52 Sponsor Protocol Number: AX.- CL – 06a Start Date*: 2004-11-12
    Sponsor Name:Axonyx Corporation
    Full Title: A Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Two Different Dosages of Phenserine-tartrate in Patients with Mild to Moderate Probable Alzheimer’s Disea...
    Medical condition: Alzheimer’s Disease is a chronic progressive illness leading to loss of cognitive and intellectual abilities such as memory function, judgement and abstract thinking. In addition to the cognitive d...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10001896 Prim
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023627-14 Sponsor Protocol Number: 201052 Start Date*: 2011-02-09
    Sponsor Name:Santen Oy
    Full Title: Cross-sectional study to investigate the occurence and severity of signs and symptoms of ocular surface disease in patients with ongoing chronic topical treatment for glaucoma or ocular hypertension.
    Medical condition: Glaucoma or ocular hypertension
    Disease: Version SOC Term Classification Code Term Level
    12.1 10030043 Ocular hypertension LLT
    12.1 10018304 Glaucoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 13:04:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA